The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Priyanka Jaju
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Priyanka Jaju, a promoter of Godavari Drugs Limited, has acquired 1,00,000 convertible warrants through a preferential allotment on 18 March 2026. Before this acquisition, she held 1,85,000 equity shares representing 2.46% of the company's voting capital. After acquiring the warrants, her total holding rises to 2,85,000 securities (shares plus warrants). The acquisition accounts for 0.80% of the total share capital of the company. The company's total equity share capital also expanded from 75.30 lakh shares to 1.01 crore shares as part of the preferential issue, with the fully diluted capital standing at 1.25 crore shares.
This is a positive signal showing promoter confidence, as Priyanka Jaju is personally increasing her stake in the company via warrants. However, the size of the acquisition is small, and since these are warrants (not shares yet), the immediate voting rights impact is limited.